Currently Being Held as Live Virtual Webinars
Nurses play an increasingly important role in the treatment of patients with advanced prostate cancer. Because treatment sequencing is evolving rapidly, as more research data is collected, it is imperative that nurses become more experienced in the understanding of this disease and therapeutic options. Since nurses often act as advocates on behalf of the patient and are integral in the management of treatment side effects and physiological manifestations of advanced prostate cancer, it is imperative that they be knowledgeable in both the basics of standards of care and any new data/therapies that could help to improve patient outcomes. Since the side effects of treatments depend mainly on the type and extent of the treatment, nurses need to be kept current on the latest treatment options available as well as how to best manage their associated side effects in order to optimize patient adherence and overall outcomes.
This 1.5 hour interactive CNE educational activity will feature experts in the treatment of advanced prostate cancer. This activity is designed to help nurses better understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient management.
Oncology nurses, advanced practice nurses and nurse practitioners that treat patients with castrate resistant prostate cancer
•Review efficacy data from recent clinical trials for men with metastatic hormone-sensitive prostate cancer (mHSPC) and how oral androgen receptor inhibitor can improve outcomes for men with mHSPC.
•Discuss efficacy and safety data from recent clinical trials in castration-resistant prostate cancer (CRPC) assessing hormone, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination
•Evaluate individualized treatment plans for patients with castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer (mHSPC)
•Discuss utilizing tissue to categorize individual genomic abnormalities which are now common and crucial for genomic driven trials and therapeutic options.
•Implement best practice strategies to minimize or manage disease and treatment-associated complications to improve quality of life
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556
SUNA designates this Live Activity for 1.5 Continuing Nursing Education contact hours. This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses. This activity is approved for 1.5 ILNA certification points.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Disclaimer: “ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program"
This educational activity is supported by an educational grant from Astellas and Pfizer, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.